Department of Medicine, University of Alberta, 8-130 Clinical Sciences Building, 11350 83rd Avenue NW, Edmonton, AB, T6G 2G3, Canada.
Department of Medicine, Division of Rheumatology, University of Alberta, Edmonton, AB, Canada.
Clin Rheumatol. 2019 Jul;38(7):2015-2016. doi: 10.1007/s10067-019-04577-3. Epub 2019 May 1.
Leflunomide is a disease-modifying anti-rheumatic drug (DMARD) used in the management of rheumatoid arthritis (RA) and psoriatic arthritis. Commonly reported adverse effects include diarrhea, nausea, hepatotoxicity, hypertension, and transient global hair loss; however, additional side effects may be associated with the medication not reported in the monograph. We describe a rare case of reversible alopecia areata (AA) associated with the use of leflunomide and provide a literature review of three published similar cases. We use the Naranjo adverse drug reaction score to show the AA in our case is a "probable" side effect of leflunomide. Currently, AA is not listed as an adverse effect in the leflunomide product monograph. However, it would appear that based on our case and the three other reported cases, the likelihood of AA being an adverse effect of leflunomide is at least possible to probable.
来氟米特是一种用于治疗类风湿关节炎（RA）和银屑病关节炎的疾病修饰抗风湿药物（DMARD）。常见的不良反应包括腹泻、恶心、肝毒性、高血压和暂时性全秃；然而，与专论中未报告的药物相关的其他副作用可能会出现。我们描述了一例与来氟米特使用相关的罕见的斑秃（AA）病例，并对三篇已发表的类似病例进行了文献回顾。我们使用 Naranjo 药物不良反应评分来表明我们病例中的 AA 是来氟米特的“可能”副作用。目前，AA 并未被列为来氟米特产品专论中的不良反应。然而，根据我们的病例和其他三个已报告的病例，AA 作为来氟米特的不良反应的可能性至少是可能的。
